Table Graph
      published meta-analysis   sensitivity analysis   studies

placebo in COVID 19 all comers - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsNIH NIAID ACTT-1, 2020 (REV) 1.37 [0.97; 1.93] 1.37[0.97; 1.93]NIH NIAID ACTT-1, 2020 (REV)10%1,062NAnot evaluable deathsdetailed resultsNIH NIAID ACTT-1, 2020 (REV) 1.82 [1.20; 2.76] 1.82[1.20; 2.76]NIH NIAID ACTT-1, 2020 (REV)10%1,062NAnot evaluable deaths (time to event analysis only)detailed resultsNIH NIAID ACTT-1, 2020 (REV) 1.82 [1.20; 2.76] 1.82[1.20; 2.76]NIH NIAID ACTT-1, 2020 (REV)10%1,062NAnot evaluable clinical improvementdetailed resultsNIH NIAID ACTT-1, 2020 (REV) 0.78 [0.67; 0.89] 0.78[0.67; 0.89]NIH NIAID ACTT-1, 2020 (REV)10%1,062NAnot evaluable clinical improvement (28-day)detailed resultsNIH NIAID ACTT-1, 2020 (REV) 0.74 [0.57; 0.97] 0.74[0.57; 0.97]NIH NIAID ACTT-1, 2020 (REV)10%1,062NAnot evaluable clinical improvement (time to event analysis only)detailed resultsNIH NIAID ACTT-1, 2020 (REV) 0.78 [0.67; 0.89] 0.78[0.67; 0.89]NIH NIAID ACTT-1, 2020 (REV)10%1,062NAnot evaluable serious adverse eventsdetailed resultsNIH NIAID ACTT-1, 2020 (REV) 1.39 [1.04; 1.84] 1.39[1.04; 1.84]NIH NIAID ACTT-1, 2020 (REV)10%1,063NAnot evaluable deep vein thrombosisdetailed resultsNIH NIAID ACTT-1, 2020 (REV) 1.56 [0.55; 4.43] 1.56[0.55; 4.43]NIH NIAID ACTT-1, 2020 (REV)10%1,063NAnot evaluable elevated liver enzymesdetailed resultsNIH NIAID ACTT-1, 2020 (REV) 1.49 [0.85; 2.61] 1.49[0.85; 2.61]NIH NIAID ACTT-1, 2020 (REV)10%1,063NAnot evaluable hyperbilirubinemiadetailed resultsNIH NIAID ACTT-1, 2020 (REV) 1.19 [0.43; 3.30] 1.19[0.43; 3.30]NIH NIAID ACTT-1, 2020 (REV)10%1,063NAnot evaluable pulmonary embolismdetailed resultsNIH NIAID ACTT-1, 2020 (REV) 1.04 [0.21; 5.16] 1.04[0.21; 5.16]NIH NIAID ACTT-1, 2020 (REV)10%1,063NAnot evaluable renal impairmentdetailed resultsNIH NIAID ACTT-1, 2020 (REV) 0.98 [0.62; 1.56] 0.98[0.62; 1.56]NIH NIAID ACTT-1, 2020 (REV)10%1,063NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-06-29 09:42 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 94 - treatments: 650 - roots T: 650

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons